Sign inJoin waitlistJoin the waitlist

Olugbenga Olowokure

Hematology & Oncology · University of Cincinnati Physicians Company LLC

Credentials: · · ·

Research

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Targeted Oncology · 2017 · 102 citations
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic…
Annals of Oncology · 2015 · 91 citations
Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer
American Journal of Clinical Oncology · 2019 · 76 citations

Syed Ahmad
13 papers
Jordan Kharofa
12 papers
Davendra Sohal
9 papers
Sameer Patel
9 papers
Ann Choe
8 papers
Greg Wilson
8 papers · 1 as a fellow
Milton Smith
6 papers
Shimul Shah
5 papers
AD
Aaron Delman
4 papers · 4 as a resident
Kevin Turner
4 papers · 4 as a resident
Tahir Latif
4 papers
Jeffrey Sussman
3 papers

Clinical trials

Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
Principal investigator · Terminated · Phase 1, Phase 2
Olugbenga Olowokure
2012–2014
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2026–2030